KRAS and non-small cell lung carcinoma: In contrast, Noordhof et al.21found no survival difference by KRAS mutation after ICB monotherapy, and Mok et al.22(KEYNOTE-042, Pembrolizumab versus chemotherapy for previously untreated, PD-L1-expressing, locally advanced or metastatic NSCLC) observed clinical benefit from pembrolizumab regardless of KRAS status compared with chemotherapy.